The arrival was announced before the European market of slimming pills sold without order, is already generating intense debate: some see it as a "teaching tool", others point to the risk of an increase in eating disorders. To his supporters, it may be a "helping hand" to patients who are obese or overweight, to encourage them to view or an "educational tool" to learn how to spot hidden fats in food.
In English, the trade name implicitly present as a new ally (Ally) in the fight against overweight and obesity: Alli is OTC in the U.S. since June 2007. According to GlaxoSmithKline (GSK) Alli is now the third self-medicating product sold overseas. The European Medicines Agency (EMEA) has authorized the placing on the market without a prescription in the European Union.
Alli is not a new drug: it is a kind of semi-stamp of Xenical (orlistat), a drug against obesity sold by prescription only. GSK has an agreement with the Swiss laboratory Roche to make a version 60 mg instead of 120 mg for Xenical. This is a gastric lipase inhibitor that reduces fat absorption ingested during a meal. It is designed for obese people (12.4% of the French population) or obese (29%). For Alli, GSK retains the threshold of body mass index (weight / height in inches squared) greater than 28 (given that obesity is defined as a BMI equal to or greater than 30, and between 25 and 29 overweight).
It is in no way help to refine its shape before the summer, let alone a miracle pill: taking orlistat must be accompanied by a low calorie diet, poor fat, and exercise to help weight loss. In contrast, others fear that self-medication against the overweight, the first authorized sale free amplifies eating disorders (boulimie. ..) and attracts an audience eager to refine your silhouette before the beach.
We can, once again, advise you to talk to your doctor before deciding to use this medication
Sources and copyrights
AFP / GOOGLE
Carevox
Nouvel Observateur
0 comments:
Post a Comment